Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Warrant (NQ: NXLIW )

0.1203 -0.0127 (-9.55%)
Streaming Delayed Price Updated: 10:37 AM EDT, Aug 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,200
Open 0.1203
Bid (Size) 0.1203 (2)
Ask (Size) 0.1329 (1)
Prev. Close 0.1330
Today's Range 0.1203 - 0.1330
52wk Range 0.0075 - 0.5600
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Closing of $5.2 Million Public Offering
From Nexalin Technology, Inc.
Via GlobeNewswire

Performance

YTD
+1504.00%
+1504.00%
1 Month
-33.20%
-33.20%
3 Month
-14.07%
-14.07%
6 Month
+379.28%
+379.28%
1 Year
+299.67%
+299.67%

More News

Read More
Nexalin Technology Announces Pricing of $5.2 Million Public Offering
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
From Nexalin Technology, Inc.
Via GlobeNewswire
MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
Via ACCESSWIRE
Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
From Nexalin Technology, Inc.
Via GlobeNewswire
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Unveils Next-Generation HALO™ Clarity
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
From Nexalin Technology, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.